Chimeric Antigen Receptor Modified T Cells Infusion
Non Hodgkin Lymphoma
University of Texas Southwestern Medical CenterCell therapyPhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 81/ 100
Competitive context
66 Active assets in the Non Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Hoffmann-La Roche | Phase 3 | BB |
Acalabrutinib Narendranath Epperla | Phase 2 | BB |
Tafasitamab Paolo Caimi, MD | Phase 2 | B |
PRILOCAINE Federal University of Minas Gerais | Phase 4 | B |
LIDOCAINE Federal University of Minas Gerais | Phase 4 | B |
View all 50 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →